How to Design Effective siRNA Molecules to Silence Specific Genes

A patent detailing the precise chemical structure and sequence requirements for siRNA molecules designed to effectively turn off the AAT gene in cells.

What it covers

This patent describes the structural requirements for small interfering RNA (siRNA) molecules used to trigger gene silencing. It specifies that the molecule must consist of a sense and antisense strand, each between 19 and 30 nucleotides long, forming a duplex region. Crucially, the antisense strand must be a complement to a specific target sequence identified as SEQ ID NO:465, which corresponds to the AAT gene. The patent allows for variations in the presence or absence of short nucleotide overhangs at the ends of the duplex.

What it doesn't cover

• —Does not cover siRNA molecules that target genes other than the AAT gene specified by SEQ ID NO:465.
• —Does not cover RNA molecules longer than 30 nucleotides.
• —Does not cover single-stranded RNA molecules.
• —Does not cover methods of delivering these molecules into a living organism.

The clever bit

The innovation lies in the rational design criteria: by strictly defining the length (19-30 nucleotides) and the exact sequence complement required for the antisense strand, the inventors ensure the siRNA molecule is optimized for the cell's natural silencing machinery, minimizing off-target effects.

Why it matters

This patent is significant for the field of RNA interference (RNAi), a biological process where RNA molecules inhibit gene expression. By defining the exact sequence and structural parameters for targeting the AAT gene—often associated with Alpha-1 Antitrypsin deficiency—it provides a blueprint for developing therapeutic reagents that can precisely 'switch off' disease-causing genes.

Real-world examples

• 1.RNA interference research tools
• 2.Experimental gene silencing therapies for Alpha-1 Antitrypsin deficiency